109 related articles for article (PubMed ID: 18754682)
1. Computer simulations reveal a novel nucleotide-type binding orientation for ellipticine-based anticancer c-kit kinase inhibitors.
Thompson D; Miller C; McCarthy FO
Biochemistry; 2008 Sep; 47(39):10333-44. PubMed ID: 18754682
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.
Vendôme J; Letard S; Martin F; Svinarchuk F; Dubreuil P; Auclair C; Le Bret M
J Med Chem; 2005 Oct; 48(20):6194-201. PubMed ID: 16190746
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
Foster R; Griffith R; Ferrao P; Ashman L
J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
[TBL] [Abstract][Full Text] [Related]
4. A new twist in the transmembrane signaling tool-kit.
Lemmon MA; Ferguson KM
Cell; 2007 Jul; 130(2):213-5. PubMed ID: 17662934
[TBL] [Abstract][Full Text] [Related]
5. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
Cao H; Zhang H; Zheng X; Gao D
J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
[TBL] [Abstract][Full Text] [Related]
6. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process.
Zou J; Wang YD; Ma FX; Xiang ML; Shi B; Wei YQ; Yang SY
Proteins; 2008 Jul; 72(1):323-32. PubMed ID: 18214972
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.
Yuzawa S; Opatowsky Y; Zhang Z; Mandiyan V; Lax I; Schlessinger J
Cell; 2007 Jul; 130(2):323-34. PubMed ID: 17662946
[TBL] [Abstract][Full Text] [Related]
8. Discovery of amido-benzisoxazoles as potent c-Kit inhibitors.
Kunz RK; Rumfelt S; Chen N; Zhang D; Tasker AS; Bürli R; Hungate R; Yu V; Nguyen Y; Whittington DA; Meagher KL; Plant M; Tudor Y; Schrag M; Xu Y; Ng GY; Hu E
Bioorg Med Chem Lett; 2008 Sep; 18(18):5115-7. PubMed ID: 18723346
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
Healy EF; Johnson S; Hauser CR; King PJ
FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
[TBL] [Abstract][Full Text] [Related]
10. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
[TBL] [Abstract][Full Text] [Related]
11. DNA binding ellipticine analogues: synthesis, biological evaluation, and structure-activity relationships.
Ferlin MG; Marzano C; Gandin V; Dall'Acqua S; Dalla Via L
ChemMedChem; 2009 Mar; 4(3):363-77. PubMed ID: 19197924
[TBL] [Abstract][Full Text] [Related]
12. Pattern recognition methods investigation of ellipticines structure-activity relationships.
de Melo LC; Braga SF; Barone PM
J Mol Graph Model; 2007 Mar; 25(6):912-20. PubMed ID: 17049892
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
[TBL] [Abstract][Full Text] [Related]
15. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.
Poljaková J; Frei E; Gomez JE; Aimová D; Eckschlager T; Hrabeta J; Stiborová M
Cancer Lett; 2007 Jul; 252(2):270-9. PubMed ID: 17306925
[TBL] [Abstract][Full Text] [Related]
16. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
Srikakulam SK; Bastys T; Kalinina OV
Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065
[TBL] [Abstract][Full Text] [Related]
17. The anticancer agent ellipticine unwinds DNA by intercalative binding in an orientation parallel to base pairs.
Canals A; Purciolas M; Aymamí J; Coll M
Acta Crystallogr D Biol Crystallogr; 2005 Jul; 61(Pt 7):1009-12. PubMed ID: 15983425
[TBL] [Abstract][Full Text] [Related]
18. c-Kit--a hematopoietic cell essential receptor tyrosine kinase.
Edling CE; Hallberg B
Int J Biochem Cell Biol; 2007; 39(11):1995-8. PubMed ID: 17350321
[TBL] [Abstract][Full Text] [Related]
19. Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit.
Hu E; Tasker A; White RD; Kunz RK; Human J; Chen N; Bürli R; Hungate R; Novak P; Itano A; Zhang X; Yu V; Nguyen Y; Tudor Y; Plant M; Flynn S; Xu Y; Meagher KL; Whittington DA; Ng GY
J Med Chem; 2008 Jun; 51(11):3065-8. PubMed ID: 18447379
[TBL] [Abstract][Full Text] [Related]
20. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
